Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer

Published:2020-01-20 Issue:10 Volume:28 Page:4687-4695
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Banna Giuseppe L.^ORCID,Urzia Valeria,Benanti Chiara,Pitrè Alessandra,Lipari Helga,Di Quattro Rosario,De Giorgi Ugo,Schepisi Giuseppe,Basso Umberto,Bimbatti Davide,Rundo Francesco,Libra Massimo,Malatino Lorenzo

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-020-05311-5.pdf

Reference28 articles.

1. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS (2019) Managing nonmetastatic castration-resistant prostate cancer. Eur Urol 75(2):285–293. https://doi.org/10.1016/j.eururo.2018.07.035

2. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 75(1):88–99. https://doi.org/10.1016/j.eururo.2018.03.028

3. Banna GL, Collova E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferrau F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36(8):595–605. https://doi.org/10.1016/j.ctrv.2010.04.005

4. Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, Pirl WF, Temel JS, Greer JA (2017) Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract 13(5):e474–e485. https://doi.org/10.1200/JOP.2016.019729

5. Gebbia V, Bellavia M, Banna GL, Russo P, Ferrau F, Tralongo P, Borsellino N (2013) Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clinical lung cancer 14(4):390–398. https://doi.org/10.1016/j.cllc.2012.11.007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27

2. Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study;Scientific Reports;2024-02-28

3. Effect of using a mobile drug management application on medication adherence and hospital readmission among elderly patients with polypharmacy: a randomized controlled trial;BMC Health Services Research;2023-11-02

4. Adherence to Hormonal Therapies in Prostate Cancer;Urology Practice;2023-11

5. Effect of using drug management application on drug adherence and outcomes in older adults with polypharmacy: a randomized clinical trial study;2023-07-27